# Third Harmonic Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/third-harmonic-bio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.thirdharmonicbio.com/
- Total disclosed funding: $155M
- Latest round: Series B (Feb 16, 2022)
- Investors on record: 10

## About

Third Harmonic Bio, Inc. is a US-based biopharmaceutical company focused on developing therapies for chronic urticaria and severe asthma, utilizing innovative biological mechanisms to address unmet medical needs.Third Harmonic Bio, Inc. specializes in creating biopharmaceutical solutions for chronic urticaria and severe asthma. Founded in 2019 and headquartered in San Francisco, US. In September 2022, Third Harmonic Bio, Inc. raised USD 163.35 million in an IPO, selling 12.5 million shares at USD 17 per share on the Nasdaq Global Select Market.Third Harmonic Bio develops innovative therapies primarily targeting chronic urticaria and severe asthma. Their flagship product, THB335, aims to inhibit biological pathways linked to allergic responses, offering relief to patients. The products are marketed mainly in the US, with potential interest in international markets as clinical trials progress.The revenue model of Third Harmonic Bio is based on collaborations with healthcare providers and agreements with pharmaceutical distributors. These partnerships focus on the development and commercialization of biopharmaceutical products, allowing integration of THB335 into treatment protocols for allergic conditions, with revenue streams expected to strengthen following successful clinical trials.

## Funding rounds

- Series B, Feb 16, 2022, $105M — Atlas Venture, OrbiMed Advisors, General Atlantic, RTW Investments, BVF Partners, RA Capital Management, Boxer Capital, Ajax Health, Commodore Capital, Deep Track Capital
- Series A, Jun 1, 2019, $50M — Atlas Venture, OrbiMed Advisors, BVF Partners

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A, Series B
- General Atlantic (https://capitalatlas.ai/funds/general-atlantic) — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- Ajax Health — Series B
- Commodore Capital (https://capitalatlas.ai/funds/commodore-capital) — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B